General Information of Drug (ID: DMY4IWC)

Drug Name
LCB-2183 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
135418284
CAS Number
CAS 133914-85-9
TTD Drug ID
DMY4IWC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Histamine receptor (HR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Histamine Phosphate DMV7IM6 Diagnostic imaging N.A. Approved [3]
Repirinast DM6KI0D Asthma CA23 Approved [4]
Levomequitazine DMAYC76 Seasonal allergic rhinitis CA08.01 Phase 3 [5]
ETX-9101 DMZOA2L Asthma CA23 Phase 2 [6]
ETS-6218 DMV96BY Fibromyalgia MG30.01 Phase 2 [6]
Votucalis DMW4LTI Allergic rhinitis CA08.0 Phase 2 [7]
OX-NLA DMPEHBJ Allergic rhinitis CA08.0 Discontinued in Phase 3 [8]
Tesmilifene DMPB36I Breast cancer 2C60-2C65 Discontinued in Phase 2 [9]
CP-118 DMNJD9H Allergic rhinitis CA08.0 Discontinued in Phase 2 [10]
REV-598 DM314CZ Carcinoid syndrome 5B10 Terminated [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine receptor (HR) TT7CXIM NOUNIPROTAC Modulator [2]

References

1 LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Eur J Pharmacol. 1995 Aug 25;282(1-3):103-9.
2 LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
5 Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
6 Clinical pipeline report, company report or official report of e-Therapeutics.
7 CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
8 Clinical pipeline report, company report or official report of Orexo.
9 Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)